Bone Marrow Transplantation for Hodgkin's Disease-Recent Advances and Current Issues

References

• Moore M. R., Jones S. E., Bull J. M., et al. MOPP chemotherapy for advanced Hodgkin's disease: prognostic factors in 81 patients. Cancer 1973; 32: 52–60
   PubMed Web of Science ®Google Scholar
• Fisher R. I., DeVita V. T., Hubbard S. P., et al. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Annals of Internal Medicine 1979; 90: 761–763
   PubMed Web of Science ®Google Scholar
• Mauch P., Ryback M., Rosenthal D., et al. The influence of initial pathologic stage on the survival of patients who relapse from Hodgkin's disease. Blood 1980; 56: 892–897
   PubMed Web of Science ®Google Scholar
• Roach M., Kapp D. S., Rosenberg S. A., et al. Radiotherapy with curative intent: An option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease. J. Clin. Oncol. 1987; 5: 550–557
   PubMed Web of Science ®Google Scholar
• Fox K. A., Lippman S. M., Cassady J. R., et al. Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. JCO. 1987; 5: 38–45
   PubMed Web of Science ®Google Scholar
• Longo D. L., Duffey P. L., Young R. C., et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J. Clin. Oncol. 1992; 10: 210–218
   PubMed Web of Science ®Google Scholar
• Santoro A., Bonfante V., Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Annals of Internal Medicine 1982; 96: 139–144
   PubMed Web of Science ®Google Scholar
• Case D. C., Young C. W., Lee B. J. Combination chemotherapy of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, decarbazine, and vinblastine (ABVD). Cancer 1977; 39: 1382–1386
   PubMed Web of Science ®Google Scholar
• Krikorian J. G., Portlock C. S., Rosenberg S. A. Treatment of advanced Hogkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy. Cancer 1978; 41: 2107–2111
   PubMed Web of Science ®Google Scholar
• Sutcliffe S. B., Wrigley P. F.M., Stansfield A. G., et al. Adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) therapy for advanced Hodgkin's disease resistant to mustine, vinblastine, procarbazine, and predni-sone (MVPP). Cancer Chemother. Pharmacol. 1979; 2: 209–213
   PubMed Web of Science ®Google Scholar
• Piga A., Ambrosetti A., Todeschinit G., et al. Doxorub-icin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease. Cancer Treatment Reports 1984; 68: 947–951
   PubMedGoogle Scholar
• Tannir N., Hagemeister F., Velasquez W., Cabanillas F. Long-term follow-up with ABDIC stage chemotherapy of MOPP-resistant Hodgkin's disease. J. Clin. Oncol. 1983; 1: 432–439
   PubMed Web of Science ®Google Scholar
• Bergsagel D. E. Salvage treatment for Hodgkin's disease in relapse. J. Clin. Oncol. 1987; 525–526, Editorial
   PubMed Web of Science ®Google Scholar
• Hryniuk W. M. Integrating the concept of dose intensity into a strategy for systemic therapy of malignant disease. Prog. Clin. Biol. Res. 1990; 354B: 93–101
   PubMedGoogle Scholar
• Frei E., III, Antman K., Teicher B., Eder P., Schnip-per L. Bone marrow autotransplantation for solid tumors- Prospects. J. Clin. Oncol. 1989; 7: 515–526
   PubMed Web of Science ®Google Scholar
• Deisseroth A., Abrams R. A. The role of autologous stem cell reconstitution in intensive therapy for resistant neoplasms. Cancer Treatment Rep. 1979; 63: 461–471
   PubMedGoogle Scholar
• Jagannath S., Dicke K. A., Armitage J. O., et al. High dose cyclophosphamide, carmustine, and etoposide for relapsed Hodgkin's disease. Ann. Intern. Med. 1986; 104: 163–168
   PubMed Web of Science ®Google Scholar
• Philip T., Dumont J., Teillet F., et al. High-dose chemotherapy and autologous bone marrow transplantation in refractory Hodgkin's disease. Br. J. Cancer 1986; 53: 737–742
   PubMed Web of Science ®Google Scholar
• Jagannath S., Armitage J. O., Dicke K. A., et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J. Clin. Oncol. 1989; 7: 179–185
   PubMed Web of Science ®Google Scholar
• Sullivan K. M., Appelaum F. R., Horning S. J., Rosenberg S. A., Thomas E. D. Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation. Int. J. Cell Cloning 1986; 4: 94–106
   PubMedGoogle Scholar
• Yahalom J., Gulati S., Shank B., Clarkson B., Fuks Z. Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease. Int. J. Radial. Oncol. Biol. Phys. 1989; 17: 915–922
   Web of Science ®Google Scholar
• Wheeler C., Antin J. H., Churchill W. H., et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: A dose-finding study. J. Clin. Oncol. 1990; 8: 648–656
   PubMed Web of Science ®Google Scholar
• McMillan A., Goldstone A. What is the value of autologous bone marrow transplantation in the treatment of relapsed or resistant Hodgkin's disease. Leuk. Res. 1991; 15: 237–243
   PubMed Web of Science ®Google Scholar
• Carella A. M., Carlier P., Congiu A., et al. Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin's disease in first complete remission after MOPP/ABVD protocol. Bone Marrow Transplant. 1991; 8: 99–103
   PubMed Web of Science ®Google Scholar
• Carella A. M., Carlier P., Congiu A., et al. Nine years' experience with ABMT in 128 patients with Hodgkin's disease: An Italian study group report. Leukemia 1991; 5 Suppl. 1: 68–71
   PubMed Web of Science ®Google Scholar
• Reece D. E., Barnett M. J., Connors M. J., et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J. Clin. Oncol. 1991; 9: 1871–1879
   PubMed Web of Science ®Google Scholar
• Armitage J. O., Biertnan P. J., Vose J. M., et al. Autologous bone marrow transplantation for patients with rel-pased Hodgkin's disease. Am. J. Med. 1991; 91: 605–611
   PubMed Web of Science ®Google Scholar
• Desch C. E., Lasala M. R., Smith T. J., Hillner B. E. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J. Clin. Oncol. 1992; 10: 200–209
   PubMed Web of Science ®Google Scholar
• Lohri A., Barnett M., Fairey R. N., et al. Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia experience 1970 to 1988. Blood 1991; 77: 2292–2298
   PubMed Web of Science ®Google Scholar
• Jones R. J., Piantadosi S., Mann R. B., et al. High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease. J. Clin. Oncol. 1990; 8: 527–537
   PubMed Web of Science ®Google Scholar
• Rosenfeld C. S., Przepiorka D., Schwinghammer T. L., Buck D. S., Bloom E. J., Shadduck R. K. Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advaned non-Hodgkin's lymphoma and Hodgkin's disease. Exp. Hematol. 1991; 19: 317–321
   PubMed Web of Science ®Google Scholar
• Vriesendrop H. M., Herpst J. M., Leichner P. K., Klein J. L., Order S. E. Polyclonal Yttium labeled antifer-ritin for refractory Hodgkin's disease. Int. J. Radial. Oncol. Biol. Phys. 1989; 17: 815–821
   Web of Science ®Google Scholar
• Clark S. C., Kamen R. The human hematopoietic colony stimulating factors. Science 1987; 236: 1229
   PubMed Web of Science ®Google Scholar
• Brandt S. J., Peters W. P., Antwater S. K., et al. Effect of recombinant human granulocyte macrophage colony stimulating factoron hematopoietic reconstitution after high dose chemotherapy and autologous bone marrow transplantation. N. Engl. J. Med. 1988; 318: 869
   PubMed Web of Science ®Google Scholar
• Sheridan W. P., Morstyn G., Wolf M., et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; 2: 891–895
   PubMed Web of Science ®Google Scholar
• Taylor K. M., Jagannath S., Spitzer G., et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J. Clin. Oncol. 1989; 7: 1791–1799
   PubMed Web of Science ®Google Scholar
• Jucker M., Abts H., Li W., et al. Expression of interleu-kin-6 and interleukin-6 receptor in Hodgkin's disease. Blood 1991; 77: 2413–2418
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Talpaz M., Salewski E., Gutterman J. Phase I study of recombinant interleukin-3 in patients with bone marrow failure. Blood 1989; 571, Abstract
   Google Scholar
• Ganser A., Lindemann A., Seipelt G., et al. Effects of human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 1990; 76: 666–676
   PubMed Web of Science ®Google Scholar
• Hoelzer D., Seipelt G., Gauser A. Interleukin-3 alone and in combination with GM-CSF in the treatment of patients with neoplastic disease. Sem. Hematol. 1991; 28(Suppl 2)17–25
   PubMed Web of Science ®Google Scholar
• Civin C. I., Strauss L. C., Fackler M. J., Trischmann T. M., Wiley J. M., Loken M. R. Poisitive stem cell selection: Basic science. Prog. Clin. Biol. Res. 1990; 333: 387–402
   PubMedGoogle Scholar
• Berenson R. J., Bensinger W. I., Hill R. S., et al. En-graftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717–1722
   PubMed Web of Science ®Google Scholar
• Juttner C. A., To L. B., Haylock D. N., Dyson P. G. Peripheral blood stem cell selection, collection and auto-transplantation. Prog. Clin. Biol. Res. 1990; 333: 447
   PubMedGoogle Scholar
• Kessinger A., Armitage J. O. The evolving role of autologous peripheral stem cell transplantation following high-dose therapy for malignancies. Blood 1991; 77: 211
   PubMed Web of Science ®Google Scholar
• To L. B., Shepperd K. M., Haylock D. N., et al. Single high dose of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp. Hematol. 1990; 18: 442
   PubMed Web of Science ®Google Scholar
• Socinski M. A., Elias A., Schnipper L., Cannistra S. A., Antman K. H., Griffin J. D. Granulocyte-macrophage colony stimulating factor expands the circulating hemopoietic progenitor cell compartment in man. Lancet 1988; i: 1194–1197
   Google Scholar
• Siena S., Bregni M., Brando B., Ravagnani F., Bona-donna G., Gianni A. M. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 1905
   PubMed Web of Science ®Google Scholar
• Körbling M., Holle R., Haas R., et al. Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site. J. Clin. Oncol. 1990; 8: 978–985
   PubMed Web of Science ®Google Scholar
• Phillips G. L., Reece D. E., Lerner K. G., Connors J. M. Intensive chemotherapy and autologous peripheral blood stem cell transplantation in a patient with persistent marrow involvement with Hodgkin's disease. Bone Marrow Transplant. 1990; 6: 45–47
   PubMed Web of Science ®Google Scholar
• Kessinger A., Bierman P. J., Vose J. M., Armitage J. O. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 1991; 77: 2322–2325
   PubMed Web of Science ®Google Scholar
• Appelbaum F. R., Sullivan K. M., Thomas E. D., et al. Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkins disease. J. Clin. Oncol. 1985; 3: 1490–1494
   PubMed Web of Science ®Google Scholar